FORMELA JEAN FRANCOIS 4
4 · Korro Bio, Inc. · Filed Jun 24, 2026
Research Summary
AI-generated summary of this filing
Korro Bio (KRRO) Director Formela Jean Francois Sells Shares
What Happened
- Formela Jean Francois, a director of Korro Bio (KRRO), sold a total of 175,367 shares in open‑market transactions between June 22 and June 24, 2026, generating total proceeds of approximately $2.46 million. Individual blocks included sales at reported weighted-average prices and specific trades ranging from $13.95 to $15.10 per share (see footnotes for ranges and weighted averages).
- These were sales (not purchases or option exercises). Some of the sales were made pursuant to a Rule 10b5‑1 trading plan adopted by Francois on April 8, 2026, which is a pre-arranged plan that can indicate routine disposition rather than opportunistic timing.
Key Details
- Dates and prices: June 22–24, 2026; reported per‑share prices ranged roughly from $13.95 to $15.10. Reported weighted‑average prices and ranges are provided in the filing (see footnotes F4–F6).
- Shares sold and proceeds (by date blocks reported): total 175,367 shares for ~$2,458,583 (examples: 101,579 shares on 6/23 for $1,447,501; 40,679 shares on 6/24 for $593,913).
- Ownership after transaction: Not specified in the data you provided from the filing.
- Notable footnotes: F1 — some sales were made under a 10b5‑1 plan (adopted 4/8/2026). F2/F3 — several blocks were held by Atlas Venture funds (Atlas XI and AVOF II); Francois is a member of the related general partner entities and disclaims Section 16 beneficial ownership of those fund‑held shares except to the extent of any pecuniary interest.
- Filing timeliness: Form 4 was filed on 2026‑06‑24 for transactions through 2026‑06‑24; the filing appears timely based on the reported dates.
Context
- Sales by company directors are common and may be routine (especially when done under a 10b5‑1 plan). This filing documents dispositions only; it does not by itself indicate the director’s view of Korro Bio’s prospects.
- Several transactions were of shares held by venture funds rather than direct personal holdings; the reporting person disclaims full Section 16 beneficial ownership of those fund shares per the footnotes.
Insider Transaction Report
Form 4
Korro Bio, Inc.KRRO
FORMELA JEAN FRANCOIS
Director
Transactions
- Sale
Common Stock
[F1][F2]2026-06-22$13.95/sh−3,382$47,179→ 936,252 total(indirect: See footnote) - Sale
Common Stock
[F1][F3]2026-06-22$13.95/sh−580$8,091→ 194,075 total(indirect: See footnote) - Sale
Common Stock
[F1][F4][F2]2026-06-23$14.25/sh−101,579$1,447,501→ 834,673 total(indirect: See footnote) - Sale
Common Stock
[F1][F4][F3]2026-06-23$14.25/sh−17,426$248,321→ 176,649 total(indirect: See footnote) - Sale
Common Stock
[F1][F5][F2]2026-06-24$14.60/sh−40,679$593,913→ 793,994 total(indirect: See footnote) - Sale
Common Stock
[F1][F6][F2]2026-06-24$14.98/sh−666$9,977→ 793,328 total(indirect: See footnote) - Sale
Common Stock
[F1][F5][F3]2026-06-24$14.60/sh−6,979$101,893→ 169,670 total(indirect: See footnote) - Sale
Common Stock
[F1][F6][F3]2026-06-24$14.98/sh−114$1,708→ 169,556 total(indirect: See footnote)
Footnotes (6)
- [F1]Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026.
- [F2]These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("AVA XI LP") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
- [F3]These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (4), (5) and (6).
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.88 inclusive.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.97 to $15.10 inclusive.
Signature
/s/ Ommer Chohan, Attorney-in-fact|2026-06-24